TAT 2019 – Targeted Anticancer Therapies Congress: Industry Participation

TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development.

Add to these features the high scientific standards, informal atmosphere, and active participation by the world’s leading phase 1 investigators, and you will understand why the TAT Congress has become the prime international anticancer drug development meeting.

Fast Facts: TAT 2019 – Targeted Anticancer Therapies Congress

  • Over 500 participants
  • No parallel sessions
  • Possibility to host a satellite symposium
  • More than 70 internationally renowned faculty
  • Excellent networking opportunities

Past attendance

ESMO gratefully acknowledges the valuable contribution of the following organisations in the TAT Congresses over the years.

Past attendees
AbbVie Immodulon Therapeutics
Active Motif Janssen Pharmaceutical Research & Development, L.L.C.
Adaptive Biotechnologies Lilly
Amgen Merck KGaA
Astex Novartis
AstraZeneca France Orion Pharma
AstraZeneca MedImmune Pfizer
Bavarian Nordic PharmaMar
BMS Pierre Fabre
Boehringer Ingelheim Roche
Celgene France Sanofi
Daiichi Sankyo Cancer Enterprise Servier Oncology
GSK Syneos Health
INC Pharma Takeda
Incyte Corporation Tesaro

How can I participate in TAT 2019 – Targeted Anticancer Therapies Congress?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress. Contact the ESMO Strategic Partnerships Team for more details. We look forward to hearing from you!

Who has already signed up?

ESMO gratefully acknowledges the valuable contribution the following organisations have made to the Targeted Anticancer Therapies Congress 2019. (As of January 2019).

ESMO TAT 2019 Sponsors